Table 4.
Study | Intervention | CR – acute (%) | CC – acute (%) | CR – delayed (%) | CC – delayed (%) | Adverse events |
---|---|---|---|---|---|---|
Eisenberg et al13 | 1) Palonosetron 0.3–1.0 μg/kg | 24a | Not specified. Only stated CC slightly lower than rates of CR | n/a | n/a | Headache (19.3%), constipation (8.7%), abdominal pain (2.5%), dizziness (2.5%) |
2) Palonosetron 3 μg/kg | 46a | |||||
3) Palonosetron 10 μg/kg | 40a | |||||
4) Palonosetron 30 μg/kg | 50 | |||||
5) Palonosetron 90 μg/kg | 46a | |||||
Hesketh et al18 | Palonosetron 0.25 mg IV | 88.2 | 85.3 | 67.6 | 64.7 | Decreased appetite (5.6%), fatigue (5.6%), headache (5.6%), pyrexia (5.6%) |
Di Renzo et al9 | Palonosetron 0.25 mg IV | 90.7 | 89.5 | 88.4 | 84.9 | Constipation (7.0%), headache (5.8%), asthenia (7.0%), dizziness (1.2%) |
Boccia et al19,b | 1) Palonosetron 0.25 mg oral | 70.1 | n/a | 61.0 | n/a | Headache (3.7%–8.6%), constipation (0.6%–3.2%) |
2) Palonosetron 0.50 mg oral | 66.7 | 61.7 | ||||
3) Palonosetron 0.75 mg oral | 62.8 | 56.4 | ||||
4) Palonosetron 0.25 mg IV | 57.5 | 62.5 | ||||
Eisenberg et al20 | 1) Palonosetron 0.25 mg IV | 63.0a | n/a | 54.0 | n/a | Headache (24.1%–26.8%), constipation (9.3%–14.9%), fatigue (10.9%–13.3%) |
2) Palonosetron 0.75 mg IV | 57.1a | 56.6 | ||||
3) Dolasetron 100 mg | 52.9a | 38.7 | ||||
Gralla et al21 | 1) Palonosetron 0.25 mg IV | 81.0 | n/a | 74.1 | n/a | Headache (4.8%–5.3%) |
2) Palonosetron 0.75 mg IV | 73.5a | 64.6a | ||||
3) Ondansetron 32 mg | 68.6 | 55.1 | ||||
Choi et al22 | 1) Palonosetron 0.25 mg IV day 1 cycle 1 | 77.3 | n/a | 83.0 | n/a | Constipation (2.3%), fatigue (1.1%) |
2) Palonosetron 0.25 mg IV day 1 cycle 2 | 84.1 | 93.9 | ||||
3) Palonosetron 0.25 mg IV day 1 cycle 3 | 82.1 | 92.3 | ||||
4) Palonosetron 0.25 mg IV day 1 cycle 4 | 84.1 | 94.2 | ||||
Mattiuzzi et al23 | 1) Ondansetron 8 mg IV | n/a | n/a | 21a | n/a | Constipationc, headachec |
2) Palonosetron 0.25 mg IV from day 1 to day 5 | 31a | |||||
3) Palonosetron 0.25 mg IV on days 1, 3, and 5 | 35a | |||||
Dong et al24 | 1) Palonosetron 0.25 mg IV | 95.4a | 90.9a | 84.1 | 79.5 | Constipation (15.7%), headache (4.5%), anxiety (2.3%) |
2) Ondansetron 8 mg IV | 93.3a | 91.9a | 60.0 | 55.5 | ||
Tian et al25 | 1) Palonosetron 0.25 mg IV | n/a | 66.41a | n/a | 53.91a | Leukopenia (12.50%–15.94%), constipation (8.70%–10.16%), fatigue (8.59%–9.42%), alanine or aspartate aminotransferase elevation (6.52%–7.81%), abnormal ECG recordings (5.07%–7.81%), dizziness (7.03%–10.87%), headache (5.80%–6.25%), anemia (4.69%–6.52%), thrombocytopenia (0.78%–6.52%) |
2) Granisetron 3 mg IV | 62.32a | 52.17a |
Notes:
Not statistically significant;
this study was included in the dexamethasone and palonosetron combination section as well;
didn’t state proportion of patients experiencing these symptoms.
Abbreviations: CC, complete control; CR, complete response; ECG, electrocardiogram; IV, intravenous; n/a, not available.